Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results

Renata Ferrarotto, Diana Bell, Maria L. Rubin, Katherine A. Hutcheson, Jason M. Johnson, Ryan P. Goepfert, Jack Phan, Yasir Y. Elamin, Danice K. Torman, Carla L. Warneke, Amy C. Hessel, Adam S. Garden, Jeffrey N. Myers, Faye M. Johnson, J. Jack Lee, Andrew G. Sikora, Maura L. Gillison, Bonnie S. Glisson, Neil D. Gross

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results'. Together they form a unique fingerprint.

Medicine & Life Sciences